Caspase Inhibitor

Caspase-6-IN-1 is a Caspase-6 inhibitor with an IC₅₀ of 5.6 μM. Caspase-6-IN-1 can inhibit Caspase-6 activity and reduce lamin A hydrolysis. Caspase-6-IN-1 can be used for the research of neurodegenerative diseases such as Huntington's disease and Alzheimer's disease.

NP3-146 is a NLRP3 inflammasome inhibitor through locking the NACHT domain of NLRP3. NP3-146 shows potent inhibitory activity against IL-1β release with an IC₅₀ value of 0.171 μM in LPS (HY-D1056)/Nigericin (HY-127019)-stimulated BMDM cells. NP3-146 regulates the levels of cleaved Caspase-1 and cleaved IL-1β in cell supernatants. NP3-146 can be used for the research of inflammatory diseases.

Casp6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Casp6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Berkeleyamide C is a selective matrix metalloproteinase-3 (MMP-3) and caspase-1 inhibitor. Berkeleyamide C blocks MMP-3-mediated tumor cell invasion and metastasis, as well as the abnormal activation of inflammation and apoptosis related to caspase-1. Berkeleyamide C is promising for research of cancers and inflammation-related diseases.

C14-Tri-LAN-Gly is a highly selective and potent NOD1 agonist. C14-Tri-LAN-Gly activates NOD1. C14-Tri-LAN-Gly inhibits the expression of cleaved-caspase3. C14-Tri-LAN-Gly upregulates A20 expression. C14-Tri-LAN-Gly protects mice from lethal hepatitis by inhibiting hepatocyte Apoptosis. C14-Tri-LAN-Gly inhibits osteoblastogenesis and promots osteoclastogenesis.

Casp4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Casp4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ac-VAD-CMK is a pan inhibitor for caspase 1.

Casp7 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Casp7 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

MTAAAR is a polypeptide obtained from the enzymatic hydrolysis of C-phycocyanin (HY-D1025) and possesses neuroprotective activity. MTAAAR enhances the activities of antioxidant enzymes SOD, CAT, and GSH-Px, reduces ROS, inhibits apoptosis and acetylcholinesterase (AChE) activity in brain tissue, and decreases protein carbonyl content. In the MPTP (HY-W114750)-induced zebrafish Parkinson's disease model, MTAAAR exhibits antioxidant effects, inhibits autophagy and apoptosis, reverses the loss of dopaminergic neurons and cerebral blood vessels, and alleviates motor deficits. MTAAAR can be used for research on Parkinson's disease.

Solanesol (Standard) is the analytical standard of Solanesol (HY-N0576). This product is intended for research and analytical applications. Solanesol is an orally active aliphatic terpene alcohol. Solanesol is mainly found in tobacco and other Solanaceae plants. Solanesol induces HO-1 and Hsp70 expression, activates p38 and Akt signaling pathways, and inhibits Apoptosis (reduces caspase-3 and PARP cleavage). Solanesol has antioxidant, anti-inflammatory, and neuroprotective activities. Solanesol can be used in the research of Huntington's disease, alcoholic liver disease, chronic inflammatory pain, anxiety, Alzheimer's disease, and bipolar disorder.

Nivocasan (GS 9450; LB-84451) is a pan-caspase inhibitor that irreversibly arrests caspase-1 activity and inhibits that of caspase-8. Nivocasan inhibits IL-1β cleavage and blocks osteoclast differentiation. Nivocasan inhibits the protein expression of NFATc1 and CSTK.

NP-1815-PX is an orally active dual inhibitor of P2X4 and prostaglandin TP receptors, with an IC₅₀ of 0.26 μM against human P2X4 receptors. NP-1815-PX specifically inhibits ATP-mediated prostaglandin production, TP receptor-induced calcium elevation, and the canonical/non-canonical NLRP3 inflammasome signaling pathway. NP-1815-PX selectively blocks smooth muscle contractions induced by ATP, U46619 (HY-108566) and prostaglandin F2α. NP-1815-PX not only produces anti-allodynic effects in vivo, but also significantly alleviates symptoms of DNBS (HY-W324435)-induced colitis (such as weight loss and tissue damage). NP-1815-PX exerts anti-inflammatory effects by downregulating IL-1β levels and Caspase-1 activity. NP-1815-PX is used in studies related to asthma and inflammatory bowel disease (colitis).

Ac-YVAD-CHO (L-709049) acetate is a potent, reversible, specific tetrapeptide interleukin-lβ converting enzyme (ICE) inhibitor with mouse and human K_i values of 3.0 and 0.76 nM. Ac-YVAD-CHO acetate is also a caspase-1 inhibitor. Ac-YVAD-CHO acetate can suppress the production of mature IL-lβ.

Ac-AAVALLPAVLLALLAP-LEHD-CHO is an inhibitor of caspases 4, 5 and 9. Ac-AAVALLPAVLLALLAP-LEHD-CHO shows protective effects upon Neocarzinostatin (HY-111183)-treated MCF-7 cells.

FKA-9i is an orally active anticancer agent. FKA-9i directly binds to and promotes the degradation of oncoproteins LRPPRC (k_d: 7.387 μM), YBX1 (k_d: 16.52 μM) and RPN1 (k_d: 26.82 μM). FKA-9i inhibits the MAPK signaling pathway and mitochondrial oxidative phosphorylation. FKA-9i also induces cancer cell cycle arrest, apoptosis, mitochondrial dysfunction and ROS accumulation. FKA-9i can be used in the research of tumors such as gastric cancer.

Apoptosis inducer 56 is an apoptosis inducer. Apoptosis inducer 56 induces DNA damage (upregulation of γH2AX and p-ATM expression) by minor groove binding. Apoptosis inducer 56 induces intrinsic apoptosis (upregulation of p53 and Bax/Bcl-2 ratio, cleaved caspase-7) via S-phase cell cycle arrest. Apoptosis inducer 56 shows selectivity for cancer cells over normal breast epithelial cells. Apoptosis inducer 56 can be used for the research of breast cancer.

Ac-VDVAD-CHO is a caspase-2/3 inhibitor (IC₅₀: 46 and 15 nM).

Ac-Trp-Glu-His-Asp-Aldehyde is a potent and selective caspase-1 inhibitor with a K_i value of 56 pM.

Casp2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Casp2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HDAC6-IN-67 is a selective HDAC6 inhibitor (IC50 = 17.15 nM) that exhibits 19-fold selectivity over HDAC1. HDAC6-IN-67 selectively inhibits HDAC6 by interacting with Ser531 and His614. HDAC6-IN-67 induces apoptosis by inducing the cleavage of caspases 9, 8, 3, and PARP, upregulating Bax expression, and downregulating Bcl-2 expression. HDAC6-IN-67 effectively induces the acetylation of α-tubulin, without affecting histone H3 acetylation in MCF-7/ADR cells. HDAC6-IN-67 can be used for the study of breast cancer.